Drug Profile
Research programme: therapeutics - Dyadic International/EnGen Bio
Latest Information Update: 17 Nov 2022
Price :
$50
*
At a glance
- Originator Dyadic International; EnGen Bio
- Developer Dyadic International; EnGen Bio; Israel Institute for Biological Research
- Class Anti-infectives; Antigens; Monoclonal antibodies; Proteins; Vaccines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical COVID 2019 infections
- No development reported Unspecified
Most Recent Events
- 10 Nov 2022 Preclinical trials in COVID-2019 infections in Israel (Parenteral) as of November 2022
- 10 Nov 2022 Preclinical pharmacodynamics data from COVID-19 infections released by Dyadic International
- 28 Feb 2022 No recent reports of development identified for research development in Unspecified in Israel (Parenteral)